#BEGIN_DRUGCARD DB03343

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
Not Available

# ChEBI_ID:
Not Available

# Chemical_Formula:
C4H4O5

# Chemical_IUPAC_Name:
(2R,3Z)-2,4-dihydroxy-4-oxidobut-3-enoate

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Not Available

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Malate Like Intermediate

# HET_ID:
TEO

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C4H6O5/c5-2(4(8)9)1-3(6)7/h1-2,5-7H,(H,8,9)/p-2/t2-/m1/s1

# InChI_Key:
InChIKey=QFBHYOKSQPPXHZ-UWTATZPHSA-L

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
3343

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
132.0716

# Molecular_Weight_Mono:
132.005873238

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1P2H

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
-1

# Predicted_LogS:
0.61

# Predicted_Water_Solubility:
6.91e+02 g/l

# Primary_Accession_No:
DB03343

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
5289457

# PubChem_Substance_ID:
46505404

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT03039

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
O[C@H](\C=C(/O)[O-])C([O-])=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:22:09 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Periplasm

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
AJ132010

# Drug_Target_1_GenBank_ID_Protein:
4539587

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
fccA

# Drug_Target_1_Gene_Sequence:
>1683 bp
AACCAAGAATGTGATAGCTGCCATACACCAGATGGTGAACTGTCAAATGACAGCTTAACT
TATGAAAATACACAATGTGTATCTTGCCATGGCACACTAGAGGAAGTCGCTGAAACGACA
AAACATGAACACTATAATGCTCATGCTTCTCATTTCCCTGGCGAAGTAGCTTGTACCTCA
TGCCACAGCGCACACGAAAAATCGATGGTGTATTGTGACTCTTGCCATAGCTTCGATTTC
AACATGCCTTATGCTAAAAAATGGCAACGTGACGAGCCTACTATTGCTGAACTGGCCAAA
GATAAATCAGAACGTCAGGCTGCTCTTGCTAGCGCACCTCACGATACTGTTGACGTAGTG
GTTGTCGGTTCTGGCGGCGCAGGTTTCTCAGCAGCAATATCTGCAACAGACAGTGGTGCT
AAAGTCATTCTTATTGAAAAAGAGCCTGTTATTGGTGGTAATGCTAAGTTAGCTGCGGGT
GGCATGAACGCTGCTTGGACTGATCAACAAAAAGCCAAAAAAATTACTGACAGCCCAGAG
TTAATGTTCGAAGACACCATGAAAGGTGGCCAAAACATAAATGATCCTGCATTAGTTAAA
GTATTAAGCTCACACTCTAAAGACTCTGTTGATTGGATGACCGCTATGGGTGCCGATTTA
ACTGATGTTGGCATGATGGGTGGCGCATCTGTTAATCGTGCGCATCGTCCAACCGGTGGT
GCTGGTGTAGGTGCTCATGTTGTTCAAGTACTTTATGATAATGCAGTGAAACGCAATATC
GACTTACGCATGAACACTCGCGGCATTGAAGTGCTTAAAGATGATAAAGGCACTGTTAAA
GGTATTCTGGTTAAGGGTATGTATAAAGGTTACTACTGGGTGAAAGCCGATGCGGTAATC
TTAGCAACGGGTGGTTTCGCTAAAAATAACGAGCGTGTCGCTAAGCTTGATCCTTCACTA
AAAGGCTTTATCTCTACTAACCAACCTGGTGCAGTAGGTGATGGACTGGATGTAGCGGAA
AATGCGGGCGGCGCATTGAAAGACATGCAGTATATCCAAGCTCACCCAACACTATCTGTT
AAAGGTGGCGTAATGGTCACTGAAGCGGTTCGTGGTAATGGTGCGATTTTGGTTAACCGT
GAAGGTAAGCGTTTCGTTAACGAAATTACTACTCGTGATAAAGCATCTGCCGCTATCTTA
GCGCAAACCGGTAAATCAGCTTATTTGATTTTTGATGATTCTGTGCGTAAGTCACTGTCA
AAAATTGATAAGTATATTGGTTTAGGTGTTGCACCAACCGCAGATAGCCTAGTTAAATTA
GGTAAAATGGAAGGTATTGACGGCAAAGCATTGACTGAAACTGTCGCGCGTTACAACAGC
TTAGTGAGTAGCGGTAAAGACACTGATTTTGAGCGTCCAAACCTACCGCGCGCACTTAAC
GAAGGTAACTACTATGCAATTGAAGTTACACCTGGTGTTCACCACACTATGGGTGGCGTG
ATGATCGACACTAAAGCTGAAGTCATGAATGCTAAGAAGCAGGTTATCCCTGGCTTGTAT
GGTGCTGGTGAGGTTACTGGCGGTGTTCATGGTGCTAACCGCTTAGGTGGTAATGCTATT
TCAGACATCATCACCTTCGGTCGCTTAGCGGGTGAAGAAGCTGCAAAATATTCTAAAAAG
AAC

# Drug_Target_1_General_Function:
Energy production and conversion

# Drug_Target_1_General_References:
10479620	Pealing SL, Lysek DA, Taylor P, Alexeev D, Reid GA, Chapman SK, Walkinshaw MD: Crystallization and preliminary X-ray analysis of flavocytochrome c(3), the fumarate reductase from Shewanella frigidimarina. J Struct Biol. 1999 Aug;127(1):76-8.
12093271	Pankhurst KL, Mowat CG, Miles CS, Leys D, Walkinshaw MD, Reid GA, Chapman SK: Role of His505 in the soluble fumarate reductase from Shewanella frigidimarina. Biochemistry. 2002 Jul 9;41(27):8551-6.
12356299	Mowat CG, Pankhurst KL, Miles CS, Leys D, Walkinshaw MD, Reid GA, Chapman SK: Engineering water to act as an active site acid catalyst in a soluble fumarate reductase. Biochemistry. 2002 Oct 8;41(40):11990-6.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
3673

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
60622

# Drug_Target_1_Name:
Fumarate reductase flavoprotein subunit

# Drug_Target_1_Number_of_Residues:
571

# Drug_Target_1_PDB_ID:
1QJD

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00890	FAD_binding_2

# Drug_Target_1_Protein_Sequence:
>Fumarate reductase flavoprotein subunit
ADNLAEFHVQNQECDSCHTPDGELSNDSLTYENTQCVSCHGTLEEVAETTKHEHYNAHAS
HFPGEVACTSCHSAHEKSMVYCDSCHSFDFNMPYAKKWQRDEPTIAELAKDKSERQAALA
SAPHDTVDVVVVGSGGAGFSAAISATDSGAKVILIEKEPVIGGNAKLAAGGMNAAWTDQQ
KAKKITDSPELMFEDTMKGGQNINDPALVKVLSSHSKDSVDWMTAMGADLTDVGMMGGAS
VNRAHRPTGGAGVGAHVVQVLYDNAVKRNIDLRMNTRGIEVLKDDKGTVKGILVKGMYKG
YYWVKADAVILATGGFAKNNERVAKLDPSLKGFISTNQPGAVGDGLDVAENAGGALKDMQ
YIQAHPTLSVKGGVMVTEAVRGNGAILVNREGKRFVNEITTRDKASAAILAQTGKSAYLI
FDDSVRKSLSKIDKYIGLGVAPTADSLVKLGKMEGIDGKALTETVARYNSLVSSGKDTDF
ERPNLPRALNEGNYYAIEVTPGVHHTMGGVMIDTKAEVMNAKKQVIPGLYGAGEVTGGVH
GANRLGGNAISDIITFGRLAGEEAAKYSKKN

# Drug_Target_1_Reaction:
succinate + acceptor = fumarate + reduced acceptor

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Catalyzes fumarate reduction using artificial electron donors such as methyl viologen. The physiological reductant is unknown, but evidence indicates that flavocytochrome c participates in electron transfer from formate to fumarate and possibly also to trimethylamine oxide (TMAO). This enzyme is essentially unidirectional

# Drug_Target_1_SwissProt_ID:
P0C278

# Drug_Target_1_SwissProt_Name:
FRDA_SHEFR

# Drug_Target_1_Synonyms:
EC 1.3.99.1
Fcc3
Flavocytochrome c
Flavocytochrome c3

# Drug_Target_1_Theoretical_pI:
6.51

# Drug_Target_1_Transmembrane_Regions:
None

#END_DRUGCARD DB03343
